Market Research Report

A quick peek into the report

Market Report Coverage

PD-1/PDL-1 Inhibitor Market

Number of Tables

64

Number of Figures

124

Number of Pages

247

 

 

 

Key Companies Profiled

•    GlaxoSmithKline plc
•    Bristol-Myers Squibb Company
•    Arcus Biosciences, Inc.
•    Agenus Inc.
•    F. Hoffmann-La Roche Ltd
•    Astra Zeneca PLC
•    Beigene Ltd.
•    Shanghai Junshi Bioscience Co. Ltd.
•    Shanghai Henlius Biotech, Inc.
•    Jiangsu HengRui Medicine Co., Ltd.
•    Lee's Pharmaceutical Limited
•    Incyte Corporation
•    Biocad
•    CStone Pharmaceuticals

Industry & Technology Overview

Global PD-1/PDL-1 Inhibitor Market Overview

Programmed cell death 1 (PD-1) inhibitor and programmed death ligand 1 (PD-L1) inhibitor are therapeutic agents that inhibit binding together of these checkpoint proteins on immune cells, eventually preventing tumors to escape the host immune defense mechanism and control the disease progression. Keytruda, a PD-1 inhibitor developed by Merck Sharp and Dhome (MSD) was the first to entered the global PD-1/PDL-1 inhibitor market in 2014. Jemperli, the another PD-1 inhibitor from GlaxoSMithKline plc is the latest market entrant to the global PD-1/PDL-1 inhibitor market.

The current global PD-1/PDL-1 inhibitor market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in the PD-1/PDL-1 inhibitor market generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient.

The PD-1/PDL-1 inhibitors are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has been found to be more effective in patients demonstrating certain level of predictive biomarkers such as PDL-1 expression. However, these tests are costly and treatment specific which poses a hinderance to smooth administration of these PD-1/PDL-1 inhibitors to larger set of patients.

Several global players of the PD-1/PDL-1 inhibitor market, such as MSD, Bristol Myers Squibb Company (BMS), AstraZeneca Plc are actively pursuing research activities focussed toward maximizing the potential of PD-1/PDL-1 inhbitors. Companies in the Asia-Pacific region also have rich clinical pipeline and are strategically pursuing research activities in the PD-1/PDL-1 inhibitor market.

Competitive Landscape

There are seven product currently available in the global PD-1/PDL-1 inhibitor market. The first entrant Keytruda draws a significant share of the global PD-1/PDL-1 inhibitor market followed by second entrant Opdivo. Imfinzi and Tecentriq also have their combined market share below 20%.

Disease Landscape

In terms of most promising indication for the application of PD-1/PDL-1 inhibitors, melanoma appears to be the leading indication as highlighted by experts as well as the data gathered from secondary research.

Segmentation:

Within the research report, the segmentation has made on the basis of:

•    Identified cancer indicattions (Non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, colorectal cancer, and urothelial carcinoma), and
•    The seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).

This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Demand – Drivers and Challenges

Some of the potential drivers identified by BIS Research includes:

•    Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications
•    Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens

The market is expected to face some limitations too due to the following challenges:

•    Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern
•    Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment

Analyst Thoughts

According to Tausif, Principal Analyst, BIS Research, “Global PD-1/PDL-1 inhibitor market is expected to grow further in the coming years as more and more research activities are being pursued toward bringing more and more cancer indications under the treatment purview of PD-1/PDL-1 inhibitors and other relevant strategies being worked-upon by involved companies to maximize the potential of these agents”.

 

Download this TOC

Request a Sample

PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis

Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032

Contact Us

Get Free Sample Schedule a Call
 
Some Faq's

Frequently Asked Questions

Programmed cell death 1 (PD-1) inhibitor and programmed death ligand 1 (PD-L1) inhibitor are therapeutic agents that inhibit binding together of these checkpoint proteins on immune cells, eventually preventing tumors to escape the host immune defense mechanism and control the disease progression.

The key trends in the global PD-1/PDL-1 inhibitors market include broadening the therapeutic range of PD-1/PDL-1 inhibitors by bringing more and more indications under the treatment scope, combination treatment strategies, along with focus on synergistic activities among the companies involved in research and development of PD-1/PDL-1 inhibitors to maximize the therapeutic potential of these agents.

According to BIS Research, most of the companies preferred partnerships, collaborations, and joint ventures as a strategy to further increase their growth as well as exploring neiche indications.

A new entrant can focus on neiche indications, develop small molecule PD-1/PDL-1 inhibitor or bring more convenient and effective formulation to administer PD-1/PDL-1 inhibitor treatment.

The following can be seen as some of the USPs of the report:

· Epidemiology forecast, underlining estimated target patient population eligible to receive PD-1/PDL-1 inhibitor treatment

· Extensive competitive benchmarking of 14 key companies with their offerings in the global PD-1/PDL-1 inhibitor market

· A peek-into market dynamics of global PD-1/PDL-1 inhibitor market

This report will help companies involved in research and development of PD-1/PDL-1 inhibitors to understand the opportunity as well as competition in the segment as well it help venture capital investment firms to make informed decisions on their investment in PD-1/PDL-1 inhibitor therapeutics segment.

Similar Product

You may also like

Global PD-1/PD-L1 Immunotherapy Market
Published Year: 2020

Global PD-1/PD-L1 Immunotherapy Market: Focus on Type, Application, Country Data (14 Countries), and

The global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over...

View Report